CL2023000823A1 - Métodos para tratar trastornos asociados a la vía del receptor de melanocortina 4 - Google Patents
Métodos para tratar trastornos asociados a la vía del receptor de melanocortina 4Info
- Publication number
- CL2023000823A1 CL2023000823A1 CL2023000823A CL2023000823A CL2023000823A1 CL 2023000823 A1 CL2023000823 A1 CL 2023000823A1 CL 2023000823 A CL2023000823 A CL 2023000823A CL 2023000823 A CL2023000823 A CL 2023000823A CL 2023000823 A1 CL2023000823 A1 CL 2023000823A1
- Authority
- CL
- Chile
- Prior art keywords
- melanocortin
- methods
- disorders associated
- treat disorders
- receptor pathway
- Prior art date
Links
- 102000001796 Melanocortin 4 receptors Human genes 0.000 title abstract 4
- 108010021436 Type 4 Melanocortin Receptor Proteins 0.000 title abstract 4
- 230000037361 pathway Effects 0.000 title abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 208000035475 disorder Diseases 0.000 abstract 2
- 206010020710 Hyperphagia Diseases 0.000 abstract 1
- 208000008589 Obesity Diseases 0.000 abstract 1
- 239000000556 agonist Substances 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Child & Adolescent Psychology (AREA)
- Obesity (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Dermatology (AREA)
- Organic Chemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Cosmetics (AREA)
Abstract
La divulgación se refiere a un método para tratar un trastorno, trastorno o condición asociados al gen agonizable de la vía MC4R, tales como obesidad o hiperfagia, en un sujeto que usa un agonista del receptor de melanocortina 4 (MC4R).
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063082867P | 2020-09-24 | 2020-09-24 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2023000823A1 true CL2023000823A1 (es) | 2023-09-15 |
Family
ID=80845850
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2023000823A CL2023000823A1 (es) | 2020-09-24 | 2023-03-22 | Métodos para tratar trastornos asociados a la vía del receptor de melanocortina 4 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20240058414A1 (es) |
| EP (1) | EP4216979A1 (es) |
| JP (1) | JP2023542985A (es) |
| KR (1) | KR20230095956A (es) |
| CN (1) | CN116507353A (es) |
| AR (1) | AR123603A1 (es) |
| AU (1) | AU2021350017A1 (es) |
| CA (1) | CA3192873A1 (es) |
| CL (1) | CL2023000823A1 (es) |
| CO (1) | CO2022009561A2 (es) |
| MX (1) | MX2023003360A (es) |
| TW (1) | TW202228760A (es) |
| WO (1) | WO2022067086A1 (es) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024015880A2 (en) * | 2022-07-12 | 2024-01-18 | Rhythm Pharmaceuticals, Inc. | Methods for treating obesity with an mc4r agonist |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8039435B2 (en) * | 2005-07-08 | 2011-10-18 | Ipsen Pharma S.A.S. | Melanocortin receptor ligands |
| EP4029513A1 (en) * | 2015-09-30 | 2022-07-20 | Rhythm Pharmaceuticals, Inc. | Melanocortin-4 receptor agonists for the treatment of disorders characterised by pomc gene hypermethylation |
-
2021
- 2021-09-24 AU AU2021350017A patent/AU2021350017A1/en active Pending
- 2021-09-24 JP JP2023518779A patent/JP2023542985A/ja active Pending
- 2021-09-24 MX MX2023003360A patent/MX2023003360A/es unknown
- 2021-09-24 AR ARP210102664A patent/AR123603A1/es unknown
- 2021-09-24 CN CN202180071771.8A patent/CN116507353A/zh active Pending
- 2021-09-24 CA CA3192873A patent/CA3192873A1/en active Pending
- 2021-09-24 TW TW110135665A patent/TW202228760A/zh unknown
- 2021-09-24 WO PCT/US2021/052032 patent/WO2022067086A1/en active Application Filing
- 2021-09-24 US US18/028,117 patent/US20240058414A1/en active Pending
- 2021-09-24 KR KR1020237013822A patent/KR20230095956A/ko unknown
- 2021-09-24 EP EP21873549.6A patent/EP4216979A1/en active Pending
-
2022
- 2022-07-07 CO CONC2022/0009561A patent/CO2022009561A2/es unknown
-
2023
- 2023-03-22 CL CL2023000823A patent/CL2023000823A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2022067086A1 (en) | 2022-03-31 |
| KR20230095956A (ko) | 2023-06-29 |
| CN116507353A (zh) | 2023-07-28 |
| CA3192873A1 (en) | 2022-03-31 |
| AR123603A1 (es) | 2022-12-21 |
| CO2022009561A2 (es) | 2022-07-19 |
| TW202228760A (zh) | 2022-08-01 |
| AU2021350017A1 (en) | 2023-05-04 |
| US20240058414A1 (en) | 2024-02-22 |
| JP2023542985A (ja) | 2023-10-12 |
| MX2023003360A (es) | 2023-06-23 |
| EP4216979A1 (en) | 2023-08-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2023000823A1 (es) | Métodos para tratar trastornos asociados a la vía del receptor de melanocortina 4 | |
| GT201600227A (es) | Vectores de aav para la terapia génica de la retina y el snc | |
| ECSP17005276A (es) | Composiciones y métodos de uso para tratar trastornos metabólicos | |
| ES2692773T3 (es) | Tratamientos para la fibrosis | |
| ECSP088852A (es) | Azolopirimidinas como inhibidores de la actividad canabinoidea 1 | |
| EA201000673A1 (ru) | СПОСОБЫ И КОМПОЗИЦИИ ДЛЯ ИЗМЕРЕНИЯ АКТИВАЦИИ Wnt И ДЛЯ ЛЕЧЕНИЯ Wnt-ОПОСРЕДОВАННЫХ РАКОВЫХ ЗАБОЛЕВАНИЙ | |
| BR112018005223A2 (pt) | compostos e métodos para modular a expressão de angiotensinogênio | |
| AR053489A1 (es) | Generacion perfilado de anticuerpos terapeuticos totalmente derivados de hucal gold humanos especificos para cd38 humano | |
| CR20110103A (es) | Heteroarilos sustituidos | |
| AR059433A1 (es) | Identificacion y uso de genes blanco para el control de nematodos parasitos de plantas | |
| ECSP077421A (es) | Compuestos y composiciones como inhibidores de la actividad del receptor canabinoide 1 | |
| CL2022001256A1 (es) | Métodos y composiciones para tratar un trastorno asociado con el angiotensinogeno agt | |
| PH12017502120A1 (en) | A method and an apparatus for forming a lignin fraction, a lignin composition and its use | |
| CL2023000371A1 (es) | Composiciones y métodos para inhibir la expresión de plp1. | |
| BR112018006674A2 (pt) | método de tratamento de distúrbios associados com a via do receptor de melanocortina-4 | |
| MX2022008320A (es) | Métodos para tratar trastornos de pénfigo. | |
| CL2020001290A1 (es) | Método para el tratamiento de enfermedades gastrointestinales con tradipitant. | |
| CR20110368A (es) | Compuestos de quinazolina sustituidos | |
| WO2018150276A3 (en) | The combination of cotinine plus antioxidant for treatment resistant depression and other neuropathological conditions | |
| CL2021000126A1 (es) | Derivados de triazolquinoxalina adicionalmente sustituidos | |
| ECSP23076906A (es) | Composiciones y métodos para inhibir cetohexoquinasa (khk) | |
| BR112022015015A2 (pt) | Usos terapêuticos de tirzepatida | |
| BR112013001302A2 (pt) | métodos de uso de derivados de amida cíclica para tratar distúrbios mediados por receptor de sigma | |
| MX2023005342A (es) | Métodos para tratar padecimientos relacionados con el receptor s1p1. | |
| CU20200038A7 (es) | Compuestos derivados de pirazolo-pirrolo-pirimidina-diona como inhibidores de p2x3 |